{
    "pmcid": "8344751",
    "qa_pairs": {
        "How was the synthetic VHH phage library designed to enhance stability?": [
            "By omitting cysteines and methionines.",
            "By incorporating additional disulfide bonds.",
            "By increasing the number of glycosylation sites.",
            "By using only short CDR3 lengths."
        ],
        "What is a key structural advantage of nanobodies compared to conventional antibodies in targeting SARS-CoV-2?": [
            "Nanobodies are smaller and can access sterically inaccessible epitopes.",
            "Nanobodies have a higher molecular weight, allowing for stronger binding.",
            "Nanobodies contain multiple heavy and light chains for increased stability.",
            "Nanobodies have a longer half-life in the bloodstream than conventional antibodies."
        ],
        "What potential advantage do VHH-huFc antibodies offer over conventional antibodies?": [
            "They offer stability, manufacturability, and epitope targeting advantages.",
            "They have a higher affinity for the ACE2 receptor.",
            "They require fewer rounds of biopanning for selection.",
            "They are less likely to induce escape mutants."
        ],
        "What was the purpose of the final round of biopanning in the selection process?": [
            "To enrich for therapeutically relevant binders against the RBD.",
            "To identify nanobodies that bind to the full-length spike protein.",
            "To test the binding affinity of nanobodies against the ACE2 receptor.",
            "To evaluate the solubility and stability of selected nanobodies."
        ],
        "Which mutation was found to abrogate binding of some VHH-huFc antibodies?": [
            "E484K",
            "L452R",
            "N501Y",
            "D614G"
        ]
    }
}